KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors
Abstract KRAS mutations are broadly recognized as promising targets for tumor therapy.T cell receptors (TCRs) can specifically recognize KRAS mutant neoantigens presented by human lymphocyte antigen (HLA) and mediate T cell responses hp pavilion 15-eg1053cl to eliminate tumor cells.In the present study, we identify two TCRs specific for the 9-mer K